CUE BIOPHARMA INC logo

CUE

CUE BIOPHARMA INC

$3.28

Earnings Summary

Revenue
$0.07Mn
Net Profits
$-10.96Mn
Net Profit Margins
-16110.29%

Highlights

Revenue:

CUE BIOPHARMA INC’s revenue fell -97.16% since last year same period to $0.07Mn in the Q3 2022. On a quarterly growth basis, CUE BIOPHARMA INC has generated 161.54% jump in its revenue since last 3-months.

Net Profits:

CUE BIOPHARMA INC’s net profit jumped 15.69% since last year same period to $-10.96Mn in the Q3 2022. On a quarterly growth basis, CUE BIOPHARMA INC has generated 17.06% jump in its net profits since last 3-months.

Net Profit Margins:

CUE BIOPHARMA INC’s net profit margin fell -2869.61% since last year same period to -16110.29% in the Q3 2022. On a quarterly growth basis, CUE BIOPHARMA INC has generated 68.29% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the CUE BIOPHARMA INC post its latest quarter earnings

EPS Estimate Current Quarter
-0.31
EPS Estimate Current Year
-0.31

Highlights

EPS Estimate Current Quarter:

CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current quarter stand at -0.31 - a 17.84% jump from last quarter’s estimates.

EPS Estimate Current Year:

CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current year stand at -0.31.

Key Ratios

Key ratios of the CUE BIOPHARMA INC post its Q2 2022 earnings

Earning Per Share (EPS)
-0.37
Return on Assets (ROA)
-0.37
Return on Equity (ROE)
-0.82

Highlights

Earning Per Share (EPS):

CUE BIOPHARMA INC’s earning per share (EPS) fell -12.12% since last year same period to -0.37 in the Q2 2022. This indicates that the CUE BIOPHARMA INC has generated -12.12% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CUE BIOPHARMA INC’s return on assets (ROA) stands at -0.37.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CUE BIOPHARMA INC’s return on equity (ROE) stands at -0.82.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-03-09
-0.35
-0.37
-5.74%
2020-08-07
-0.41
-0.38
7.32%
2020-11-09
-0.36
-0.34
6.59%
2020-05-07
-0.33
-0.48
-45.45%

Company Information

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Organisation
CUE BIOPHARMA INC
Headquarters
21 Erie Street, Cambridge, MA, United States, 02139
Employees
57
Industry
Health Technology
CEO
Daniel Passeri

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*